A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Patients With Locally Advanced or Metastatic Tumors
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Atezolizumab (Primary) ; Tiragolumab (Primary) ; Bevacizumab; Capecitabine; Carboplatin; Cisplatin; Etoposide; Paclitaxel; Pembrolizumab; Pemetrexed
- Indications Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Genentech
- 05 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 04 May 2022 Planned End Date changed from 1 Nov 2022 to 5 Oct 2024.
- 04 May 2022 Planned primary completion date changed from 1 Nov 2022 to 5 Oct 2024.